Mantle Cell Lymphoma

With 2 CAR T-cell therapies now approved and more moving quickly through early-phase clinical trials, 4 healthcare experts reflected on the evolving field of CAR T-cell therapy, their understanding of its current and future applicability for patients, the process for administration and the challenges and obstacles that remain unaddressed during an Association of Community Cancer Centers interactive panel.<br /> &nbsp;

Michael Wang, MD,&nbsp;discusses the latest options for patients with relapsed MCL, while also addressing some of the challenges with these agents.

David G. Maloney, MD, PhD,&nbsp;reviews the latest developments with CAR T-cell therapy in patients with non-Hodgkin lymphoma.

In a 16-0 vote, the&nbsp;FDA&rsquo;s Oncologic Drugs Advisory Committee has recommended the approval of&nbsp;the rituximab biosimilar CT-P10 for 3 of the anti-CD20 monoclonal antibody&rsquo;s non-Hodgkin lymphoma indications.

Guidelines from the International Lymphoma Radiation Oncology Group recommend the use of proton therapy in adults with mediastinal lymphomas and for young women. Specifically, clinicians should consider proton therapy in mediastinal disease that spans below the left main stem coronary artery and is near the front of, behind, or on the left side of the heart.

Patients with mantle cell lymphoma who were treated with the combination of lenalidomide (Revlimid) and rituximab (Rituxan) continued to have durable responses and manageable side effects at 5 years of follow-up.

A look back at all the&nbsp;FDA news&nbsp;that happened in the month of&nbsp;September 2018, including several new approvals, priority reviews, a breakthrough therapy designation, and more, in a variety of cancer types.

Patients with CD30-expressing peripheral T-cell lymphoma who were treated with the combination of brentuximab vedotin and frontline chemotherapy experienced a&nbsp;statistically significant improvement in progression-free and overall survival,&nbsp;according to topline results from the phase III ECHELON-2 trial.

Philip Bierman, MD,&nbsp;discusses the current landscape of central nervous system involvement in aggressive lymphoma and the research that still needs to be conducted.

Antibody&ndash;drug conjugate therapies are making a larger impact on the treatment paradigm for patients with lymphomas, especially following promising data for brentuximab vedotin and inotuzumab ozogamicin.

Pontchartrain Cancer Center was founded in 2005 to serve an area of Louisiana that lacked the necessary resources for cancer care. This community cancer center, with 2 locations in Southeast Louisiana, accommodates any patient to walk through its doors, filling a major unmet need for the community in this rural area.

The partial clinical hold previously placed on&nbsp;trials examining tazemetostat in patients with various solid tumors and hematologic malignancies has been lifted by the FDA and enrollment has been reopened.

Mantle cell lymphoma remains an incurable disease, but according to Michael Wang, MD, it is becoming one of the most dynamic fields in oncology. In a presentation during the 2018 SOHO Annual Meeting, Wang recapped some of the biggest advancements in relapsed/refractory MCL, as well as the promise for novel therapies in this setting.

In a presentation during the 2018 SOHO Annual Meeting, Simon Rule, MD, PhD, discusses the treatment of newly-diagnosed patients with MCL, emphasizing the benefits of the watch-and-wait approach.

Bijal D. Shah, MD,&nbsp; discusses the challenge of treating this highly heterogeneous disease, how to choose the optimal treatment regimen, and the ongoing role of BTK inhibitors.

In an interview with&nbsp;<em>Targeted Oncology</em>, Simon Rule, MD, PhD, professor of Hematology at Plymouth University Medical School, United Kingdom, discusses the current treatment paradigm for MCL, as well as the potential use of BTK inhibitors for the treatment of this patient population.

Axicabtagene ciloleucel (axi-cel; Yescarta) has been approved by the European Commission as a treatment for&nbsp;adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma, following at least 2 lines of systemic therapy.&nbsp;

Tisagenlecleucel has gained approval from the European Commission as a treatment for adult&nbsp;patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.

Mutations of <em>TP53</em> and <em>WHSC1 </em>predicted poorer overall survival in patients with mantle cell lymphoma, according to results from next-generation whole-exome sequencing of 16 Chinese patients.&nbsp;The presence of these mutations may provide physicians with an important biomarker in this patient population.

Targeting EZH2, the catalytic subunit of the multiprotein PRC2, may represent an attractive therapeutic objective in malignant lymphoma, Vincent Ribrag, MD, told his audience at the American&nbsp;Association for Cancer Research&rsquo;s inaugural Advances in Malignant Lymphoma meeting.

Brad Kahl, MD,&nbsp;discusses the exciting new advancements on the horizon for the treatment of patients with MCL.

Andre Goy, MD, shares insight on the new array of treatment options for mantle cell lymphoma and how to properly implement them.